How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?

H. G. Laverty, C. Benson, E. J. Cartwright, M. J. Cross, C. Garland, Timothy R. Hammond, C. Holloway, N. McMahon, J. Milligan, B. K. Park*, Munir Pirmohamed, C. Pollard, J. Radford, N. Roome, P. Sager, S. Singh, Tobias Suter, W. Suter, Andrew W. Trafford, P. G. A. VoldersR. Wallis, Roslyn Weaver, M. York, J. P. Valentin

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)675-693
JournalBritish Journal of Pharmacology
Volume163
Issue number4
DOIs
Publication statusPublished - Jun 2011

Keywords

  • cardiovascular safety liabilities
  • medicines
  • adverse drug reaction
  • adverse event
  • patient safety
  • drug attrition

Cite this